BioCryst Pharmaceuticals (BCRX) drew investor attention after presenting new clinical and real world data on its hereditary angioedema therapies ORLADEYO and navenibart at the European Academy of Allergy and Clinical Immunology meeting in Istanbul.

At a share price of US$9.06, BioCryst has seen short term momentum pick up around the EAACI data, with a 1 day share price return of 4.14% and year to date share price return of 20.80%. However, the 1 year total shareholder return is still down 11.95% and the 5 year total shareholder return is down 45.81%, so recent enthusiasm sits against a mixed longer term record.

If you want to see how other rare disease and biotech stories are shaping up, this is a good moment to broaden your search with 39 healthcare AI stocks

With BioCryst still loss making, yet trading at US$9.06 and sitting at a steep discount to analyst targets and some intrinsic value estimates, you have to ask: is this a mispriced rare disease story, or is the market already looking ahead?

Most Popular Narrative: 57.5% Undervalued

At a last close of $9.06 against a narrative fair value of $21.30, BioCryst is framed as deeply discounted, with that gap built on detailed revenue and earnings projections.

Strong and sustainable revenue growth for ORLADEYO, supported by increasing new patient prescriptions, expanding prescriber base, and robust retention rates, positions BioCryst to capitalize on the rising prevalence and earlier diagnosis of rare diseases, likely driving sustained top line expansion and improved profit margins.

Want to see what is baked into that valuation gap? The narrative leans on compounding revenue, rising margins, and a future earnings profile that assumes a far richer multiple than today.

Result: Fair Value of $21.30 (UNDERVALUED)

However, this hinges on ORLADEYO remaining resilient against rising HAE competition and on early stage pipeline programs avoiding setbacks that could undermine those growth assumptions.

Next Steps

With sentiment split between potential upside and clear risks, this is a good time to look at the numbers yourself and move quickly. To weigh both sides in one place, start with the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop your research here. Use powerful screeners to uncover opportunities that others overlook.

• Target higher-quality upside by scanning for companies with resilient fundamentals and attractive prices using the 47 high quality undervalued stocks.
• Strengthen your income stream by checking stocks that combine robust yields with staying power through the 9 dividend fortresses.
• Limit unpleasant surprises by focusing on companies with steadier risk profiles through the 68 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.